CD69 and neoplasm: ACM derived from OGJ patients with late-stage tumours significantly decreased the expression of CD69 on the surface of CD4+ T cells compared with untreated cells (untrx: 7.43 ± 0.8 vs. late-stage: 4.29 ± 1.1%, p = 0.005) (Fig. 1A).